Claims for Patent: 10,040,859
✉ Email this page to a colleague
Summary for Patent: 10,040,859
Title: | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
Abstract: | Compositions and methods for treating a cytokine release syndrome such as chimeric antigen receptor T-cell cytokine release syndrome or hemophagocytic lymphohistiocytosis are provided. |
Inventor(s): | Behrens; Edward M. (West Chester, PA), Rood; Julia E. (Philadelphia, PA), Kambayashi; Taku (Malvern, PA) |
Assignee: | The Children\'s Hospital of Philadelphia (Philadelphia, PA) The Trustees of the University of Pennsylvania (Philadelphia, PA) |
Application Number: | 15/305,272 |
Patent Claims: | 1. A method for inhibiting or treating a cytokine-related disease or disorder in a subject, said method comprising administering to a subject an IL-33 pathway inhibitor,
wherein said cytokine-related disease or disorder is hemophagocytic lymphohistiocytosis, and wherein said IL-33 pathway inhibitor is an antibody or fragment thereof immunologically specific for IL-33 receptor (IL-33R).
2. The method of claim 1, wherein said method further comprises administering a hemophagocytic lymphohistiocytosis therapy selected from the group consisting of an immunosuppressant, glucocorticoid, cyclosporine A, etoposide, methotrexate, IL-1 blocking agent, rilonacept, canakinumab, and gevokizumab. 3. The method of claim 1, wherein said method further comprises performing a bone marrow transplant on said subject. 4. The method of claim 1, wherein said hemophagocytic lymphohistiocytosis is familial (primary) hemophagocytic lymphohistiocytosis (FHL). 5. The method of claim 1, wherein said hemophagocytic lymphohistiocytosis is secondary hemophagocytic lymphohistiocytosis (SHLH). 6. The method of claim 1, wherein said hemophagocytic lymphohistiocytosis is malignancy associated hemophagocytic lymphohistiocytosis. 7. The method of claim 1, wherein said antibody or fragment thereof is immunologically specific for the extracellular domain of IL-33R. 8. The method of claim 1, wherein said method comprises administering an antibody immunologically specific for IL-33R to the subject. 9. The method of claim 1, wherein said method comprises administering an antibody immunologically specific for the extracellular domain of IL-33R to the subject. |
Details for Patent 10,040,859
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | February 27, 2008 | 10,040,859 | 2034-04-21 |
Novartis Pharmaceuticals Corporation | ILARIS | canakinumab | For Injection | 125319 | June 17, 2009 | 10,040,859 | 2034-04-21 |
Novartis Pharmaceuticals Corporation | ILARIS | canakinumab | Injection | 125319 | December 22, 2016 | 10,040,859 | 2034-04-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |